Skip to main content

Table 3 Associations between pCR and both sTIL-0 and sTIL-3 (upper panel: pCR by baseline sTIL categories; lower panel: pCR by 3-week categories)

From: Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Arm

sTIL-0 category

pCR %

OR

p

n

NP/G

    

173

 

TIL−

22.0

1.00*

 

141

 

TIL+

56.3

4.56 [2.04–10.20]

 < .001

32

NP/C

    

138

 

TIL−

39.6

1.00*

 

111

 

TIL+

63.0

2.59 [1.09–6.17]

.032

27

Trial

    

311

 

TIL−

29.8

1.00*

 

252

 

TIL+

59.3

3.44 [1.92–6.18]

 < .001

59

NP/G

    

160

 

3wTIL−

14.5

1.00*

 

76

 

3wTIL+

32.7

2.87 [1.23–6.74]

 < .001

55

 

3wLC

51.7

6.33 [2.40–16.68]

.032

29

NP/C

    

126

 

3wTIL−

31.4

1.00*

 

70

 

3wTIL+

54.5

2.62 [0.98–6.97]

.054

22

 

3wLC

64.7

4.00 [1.68–9.51]

.002

34

Trial

    

286

 

3wTIL−

22.6

1.00*

 

146

 

3wTIL+

39.0

2.19 [1.20–3.98]

.011

77

 

3wLC

58.7

4.87 [2.58–9.19]

 < .001

63

  1. *Reference category